[Diltiazem VUFB (Diacordin Spofa) in the treatment of arterial hypertension].
In an eight-week open clinical investigation controlled by placebo in 21 hypertonic patients the author tested the calcium ion antagonist produced in Czechoslovakia, Diltiazem, VUFB. Its very favourable antihypertensive action was proved in patients with arterial hypertension stage I and II (according to WHO), using a maximal daily dose of 180 mg without the need of combination with other antihypertensive drugs, incl. diuretics. The undesirable effects were mostly weak and developed during the first 12 days of administration of the drug. Then they disappeared. Only two patients discontinued treatment on account of severe subjective complaints. In the latter patients, however, lack of confidence into the new drug played a major role.
J
J
Zicha
D004110:Diltiazem / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
D004110:Diltiazem
Diltiazem VUFB (Diacordin Spofa) v lécbĕ arteriální hypertenze.